Improving Visibility of the Pharma Supply Chain: Best Practices and Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Visibility of the Pharma Supply Chain: Best Practices and Technologies
The authors review current industry challenges and trends in managing global supply chains and propose best practices for improving visibility into those networks.


Pharmaceutical Technology
Volume 35, pp. s26-s33

Conclusion

To realize the benefits of globalization, companies must implement new strategies that capitalize on the benefits of globalization and outsourcing while reducing and controlling risks. This article has outlined key challenges to managing global life-sciences product supply chain and proposed approaches for maintaining better visibility and control over those product life cycles. Simply put, it requires the use of information that is readily available, managed correctly, and shared to help to ensure the safety, efficacy, and quality of products for all parties involved.

David J. Lennard is vice-president, and Daniel R. Matlis is founder and president, both of Axendia,
.

To read Matlis' report on outsourcing's effect on process analytical technology and quality by design, see "Has Outsourcing Derailed PAT and QbD?"

References

1. Axendia, "Achieving Global Supply Chain Visibility, Control & Collaboration in Life Sciences: Business Imperative, Regulatory Necessity" (2010), http://www.axendia.com/2010_LS_GSC.html.

2. US IPEC, "Joint Strategic Plan on Intellectual Property Enforcement" (Washington, DC, June 2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here